Oxprenolol hydrochloride (Synonyms: dl-Alprenolol, dl-Oxprenolol) |
Katalog-Nr.GC10818
One-Click Copy Product Info
|
Oxprenololhydrochlorid (Ba 39089) ist ein oral bioverfÜgbarer β-adrenerger Rezeptor (β-AR)-Antagonist mit einem Ki von 7,10 nM in einem Radioliganden-Bindungsassay unter Verwendung von Rattenherzmuskel.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 6452-73-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Oxprenolol hydrochloride is a non-selective β-adrenergic receptor blocker with a Ki value of 7.1nM in binding inhibition experiments using ³H-dihydroalprenolol (³H-DHA) in rat heart membranes treated with neuraminidase[1].
In male Wistar albino rats, preadministration of Oxprenolol hydrochloride (2mg/kg; sc; once) inhibited the thyroxine (T4)-induced increase in plasma glucagon levels[2]. Administration of Oxprenolol hydrochloride (200mg/kg/d; p.o.; 3w) to male Wistar rats produced effective beta-blockade, with peak plasma drug levels reaching those observed within the normal clinical range in humans[3].
References:
[1] Nagatomo, T et al. “Binding characteristics of 3H-dihydroalprenolol to beta-adrenoceptors of rat heart treated with neuraminidase.” Japanese journal of pharmacology vol. 33,4 (1983): 851-7.
[2] Ikeda, T et al. “Acute effect of thyroid hormone on insulin secretion in rats.” Biochemical pharmacology vol. 40,8 (1990): 1769-71.
[3] Manning, A S et al. “Abrupt withdrawal of chronic beta-blockade: adaptive changes in cyclic AMP and contractility.” Journal of molecular and cellular cardiology vol. 13,11 (1981): 999-1009.
| Animal experiment [1]: | |
Animal models | Male Wistar albino rats |
Preparation Method | L-Thyroxine (T4) was dissolved in a small volume of 0.01N (Normality) NaOH and brought to a concentration of 10µg/mL with saline. The experimental rats were given T4 (40µg/kg) subcutaneously, and control rats received vehicle alone. Oxprenolol hydrochloride (2mg/kg) or metoprolol tartrate (35mg/kg) was administered subcutaneously 30min before T4 injection. Blood was drawn from the femoral vein at 0, 30, 40, 50, 60, and 105min after injection of the β-blocker. |
Dosage form | 2mg/kg; s.c.; once |
Applications | Preadministration of Oxprenolol hydrochloride inhibited the thyroxine (T4)-induced increase in plasma glucagon levels. |
References: | |
| Cas No. | 6452-73-9 | SDF | |
| Überlieferungen | dl-Alprenolol, dl-Oxprenolol | ||
| Chemical Name | (R)-1-(2-(allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol hydrochloride | ||
| Canonical SMILES | O[C@@H](COC1=CC=CC=C1OCC=C)CNC(C)C.Cl | ||
| Formula | C15H23NO3.HCl | M.Wt | 301.81 |
| Löslichkeit | DMF: 33 mg/ml,DMSO: 25 mg/ml,Ethanol: 33 mg/ml,PBS (pH 7.2): 10 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.3133 mL | 16.5667 mL | 33.1334 mL |
| 5 mM | 662.7 μL | 3.3133 mL | 6.6267 mL |
| 10 mM | 331.3 μL | 1.6567 mL | 3.3133 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 16 reference(s) in Google Scholar.)